MOONLAKE IMMUNOTHERAPEUTICS's ticker is and the CUSIP is 61559X104. A total of 118 filers reported holding MOONLAKE IMMUNOTHERAPEUTICS in Q1 2024. The put-call ratio across all filers is 1.06 and the average weighting 0.6%.
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 21,751,284 | $956,403,957 | 26.80% |
| Cormorant Asset Management, LP | 8,494,151 | $373,487,819 | 21.58% |
| Finepoint Capital LP | 388,835 | $17,097,075 | 4.85% |
| Ghost Tree Capital, LLC | 300,000 | $13,191,000 | 4.13% |
| 5AM Venture Management, LLC | 282,313 | $12,413,303 | 2.78% |
| Logos Global Management LP | 750,000 | $32,977,500 | 2.68% |
| MPM BioImpact LLC | 343,235 | $15,092,043 | 2.34% |
| Altium Capital Management LP | 115,000 | $5,056,550 | 2.06% |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | 228,803 | $10,060,468 | 1.64% |
| Avoro Capital Advisors LLC | 2,770,000 | $121,796,900 | 1.62% |